Pharma industry keeps wary eye on huge EU policy revision
A comprehensive revision of the EU’s industry policy for pharma is underway in Brussels, with firms like Leo Pharma and Lundbeck looking closely over politicians’ shoulders. Former political advisors expect a complicated, technical, but above all else, political battle, one MEP says.
by peter thomsen, Watch Medier’s EU correspondent, translated by catherine brett
Brussels – As Europe winds down for the summer, something is picking up speed in Brussels.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
EMA gains more power to monitor medicines
For subscribers
.jpg)
.jpg&w=384&q=75)
